GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Price-to-Owner-Earnings
中文

HUTCHMED (China) (HUTCHMED (China)) Price-to-Owner-Earnings

: 19.73 (As of Today)
View and export this data going back to 2016. Start your Free Trial

As of today (2024-04-24), HUTCHMED (China)'s share price is $18.35. HUTCHMED (China)'s Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.93. It's Price-to-Owner-Earnings for today is 19.73.


The historical rank and industry rank for HUTCHMED (China)'s Price-to-Owner-Earnings or its related term are showing as below:

HCM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.04   Med: 158.19   Max: 1510
Current: 19.72

During the past 13 years, the highest Price-to-Owner-Earnings of HUTCHMED (China) was 1510.00. The lowest was 13.04. And the median was 158.19.


HCM's Price-to-Owner-Earnings is ranked better than
65.01% of 423 companies
in the Drug Manufacturers industry
Industry Median: 27.58 vs HCM: 19.72

As of today (2024-04-24), HUTCHMED (China)'s share price is $18.35. HUTCHMED (China)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.55. Therefore, HUTCHMED (China)'s PE Ratio for today is 33.36.

As of today (2024-04-24), HUTCHMED (China)'s share price is $18.35. HUTCHMED (China)'s EPS without NRI for the trailing twelve months (TTM) ended in was $0.55. Therefore, HUTCHMED (China)'s PE Ratio without NRI for today is 33.36.

During the past 13 years, HUTCHMED (China)'s highest PE Ratio without NRI was 350.00. The lowest was 20.32. And the median was 138.75.


HUTCHMED (China) Price-to-Owner-Earnings Historical Data

The historical data trend for HUTCHMED (China)'s Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 19.06

HUTCHMED (China) Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 19.06

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HUTCHMED (China) Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s Price-to-Owner-Earnings falls into.



HUTCHMED (China) Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

HUTCHMED (China)'s Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=18.35/0.93
=19.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HUTCHMED (China)  (NAS:HCM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


HUTCHMED (China) Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


HUTCHMED (China) (HUTCHMED (China)) Business Description

Traded in Other Exchanges
Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) (HUTCHMED (China)) Headlines

From GuruFocus